310 related articles for article (PubMed ID: 37087434)
1. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database.
Chen P; Zhu J; Xu Y; Huang Q; Su J; Gao Z; Feng M
BMC Nephrol; 2023 Apr; 24(1):107. PubMed ID: 37087434
[TBL] [Abstract][Full Text] [Related]
2. Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Liu C; Wei W; Yang L; Li J; Yi C; Pu Y; Yin T; Na F; Zhang L; Fu P; Zhao Y
Front Immunol; 2023; 14():1173952. PubMed ID: 37313406
[TBL] [Abstract][Full Text] [Related]
3. Acute kidney injury associated with immune checkpoint inhibitors: A pharmacovigilance study.
Zhu J; Wu J; Chen P; You K; Su J; Gao Z; Bi Z; Feng M
Int Immunopharmacol; 2022 Dec; 113(Pt A):109350. PubMed ID: 36272360
[TBL] [Abstract][Full Text] [Related]
4. More on the "Triple Whammy": antihypertensive drugs, non-steroidal anti-inflammatory agents and acute kidney injury - a case/non-case study in the French pharmacovigilance database.
Fournier JP; Sommet A; Durrieu G; Poutrain JC; Lapeyre-Mestre M; Montastruc JL;
Ren Fail; 2014 Aug; 36(7):1166-8. PubMed ID: 24826803
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitor-associated acute kidney injury in patients with cancer: a systematic review and meta-analysis of risk factors.
Yan H; Tang M; Zhu W; Yang Y
Clin Exp Nephrol; 2023 Jul; 27(7):603-612. PubMed ID: 37014535
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-Converting Enzyme Inhibitor/Receptor Blocker, Diuretic, or Nonsteroidal Anti-inflammatory Drug Use After Major Surgery and Acute Kidney Injury: A Case-Control Study.
Roberts DJ; Smith SA; Tan Z; Dixon E; Datta I; Devrome A; Hemmelgarn BR; Tonelli M; Pannu N; James MT
J Surg Res; 2021 Jul; 263():34-43. PubMed ID: 33631376
[TBL] [Abstract][Full Text] [Related]
7. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study.
Lapi F; Azoulay L; Yin H; Nessim SJ; Suissa S
BMJ; 2013 Jan; 346():e8525. PubMed ID: 23299844
[TBL] [Abstract][Full Text] [Related]
8. Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database.
Hu F; Zhai Y; Yuan L; Liang J; Xu J; Guo X; Zhou X; Lin Z; Sun J; Ye X; He J
Cancer Med; 2021 Dec; 10(24):8754-8762. PubMed ID: 34845857
[TBL] [Abstract][Full Text] [Related]
9. Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system.
Liang X; Xiao H; Li H; Chen X; Li Y
Front Immunol; 2024; 15():1396752. PubMed ID: 38745663
[TBL] [Abstract][Full Text] [Related]
10. Non-steroidal anti-inflammatory drugs, renin-angiotensin system blockade or diuretics and risk of acute kidney injury: A case-crossover study.
Weng SE; Hsu WT; Hsiao FY; Lee CM
Arch Gerontol Geriatr; 2024 Aug; 123():105394. PubMed ID: 38537386
[TBL] [Abstract][Full Text] [Related]
11. Thromboembolic events associated with immune checkpoint inhibitors: A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database.
Li H; Sun X; Sun D; Zhao J; Xu Z; Zhao P; Ma Z; Zhang Y
Int Immunopharmacol; 2021 Sep; 98():107818. PubMed ID: 34130149
[TBL] [Abstract][Full Text] [Related]
12. Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis.
Filippini DM; Gatti M; Di Martino V; Cavalieri S; Fusaroli M; Ardizzoni A; Raschi E; Licitra L
Int J Cancer; 2021 Aug; 149(3):675-683. PubMed ID: 33844854
[TBL] [Abstract][Full Text] [Related]
13. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
14. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
15. Incidence, risk factors and prognosis of acute kidney injury in patients treated with immune checkpoint inhibitors: a retrospective study.
Ji MS; Wu R; Feng Z; Wang YD; Wang Y; Zhang L; Sun XF; Chen XM; He KL; Cai GY
Sci Rep; 2022 Nov; 12(1):18752. PubMed ID: 36335144
[TBL] [Abstract][Full Text] [Related]
16. Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury.
Dreischulte T; Morales DR; Bell S; Guthrie B
Kidney Int; 2015 Aug; 88(2):396-403. PubMed ID: 25874600
[TBL] [Abstract][Full Text] [Related]
17. Time until onset of acute kidney injury by combination therapy with "Triple Whammy" drugs obtained from Japanese Adverse Drug Event Report database.
Kunitsu Y; Hira D; Morikochi A; Ueda T; Isono T; Morita SY; Terada T
PLoS One; 2022; 17(2):e0263682. PubMed ID: 35139129
[TBL] [Abstract][Full Text] [Related]
18. Facial palsy induced by immune checkpoint blockade: A systematic analysis of clinical trials and a pharmacovigilance study of postmarketing data.
Zhu J; Li J; Zheng Y; Gao S; He Z; Qiu K; Yu X; Wu J
Int Immunopharmacol; 2023 Dec; 125(Pt B):111184. PubMed ID: 37952483
[TBL] [Abstract][Full Text] [Related]
19. Incidence, mortality, and risk factors of acute kidney injury after immune checkpoint inhibitors: Systematic review and meta-analysis of real-world evidence.
Xie W; Xiao S; Li X; Huang J; Li G; Zhang Z
Eur J Intern Med; 2023 Sep; 115():88-95. PubMed ID: 37263805
[TBL] [Abstract][Full Text] [Related]
20. Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhou X; Zheng Y; Zhao X; Xu X; Cao Y; He J
Front Endocrinol (Lausanne); 2021; 12():809063. PubMed ID: 35145482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]